CureGN队列中成人及儿童膜性肾病的治疗模式
该研究评估CureGN队列中2010-2018年诊断的原发性膜性肾病患者(361例,成人324例、儿童37例)的免疫抑制治疗处方实践及PLA2R检测可及性。结果显示55%成人和58%儿童在活检后6个月内起始免疫抑制治疗,其中1/5无适应证或存在明显禁忌证;一线治疗中约半数使用环磷酰胺或钙调磷酸酶抑制剂,但皮质类固醇单药和利妥昔单抗也占一定比例。超过80%的调查中心可进行PLA2R检测。
要点
- 超过半数成人和儿童膜性肾病患者在活检后6个月内起始免疫抑制治疗,早于KDIGO推荐的6个月观察期。
- 起始治疗者中约1/5无适应证(uPCR<4 g/g)或存在禁忌证(eGFR<30 ml/min/1.73m²)。
- 一线免疫抑制方案中环磷酰胺或钙调磷酸酶抑制剂约占半数,但皮质类固醇单药和利妥昔单抗也占一定比例。
核心结论
- 提供者可能不了解或对当前KDIGO膜性肾病指南缺乏信心,治疗模式可为指南更新提供参考。
研究设计与样本
- CureGN队列研究,纳入2010-2018年诊断的原发性膜性肾病患者361例(成人324例,儿童37例),活检时未接受免疫抑制治疗且随访至少6个月。
主要发现
- 55%成人和58%儿童在活检后6个月内起始免疫抑制治疗。
- 起始治疗者中1/5无适应证(uPCR<4 g/g)或存在禁忌证(eGFR<30 ml/min/1.73m²)。
- 一线治疗中,成人16%使用环磷酰胺、40%使用钙调磷酸酶抑制剂、20%使用皮质类固醇单药、15%使用利妥昔单抗;儿童0%使用环磷酰胺、46%使用钙调磷酸酶抑制剂、27%使用皮质类固醇单药、15%使用利妥昔单抗。
- 超过80%的调查中心可进行PLA2R检测。
临床怎么用
- 临床实践中应遵循KDIGO指南,对进展风险的膜性肾病患者先观察6个月再考虑免疫抑制治疗。
- 起始免疫抑制治疗前应评估适应证(如uPCR≥4 g/g)和禁忌证(如eGFR<30 ml/min/1.73m²)。
- PLA2R检测在多数中心可及,可用于膜性肾病的诊断和监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for Glomerulonephritis recommend that patients with membranous nephropathy (MN) at risk for progression receive immunosuppressive therapy (IST), usually after 6 months of observation. A cyclophosphamide (CYC) or calcineurin inhibitor (CNI)-based regimen is recommended as first-line IST. However, the extent to which KDIGO recommendations are adopted in practice remains largely unknown. METHODS: We evaluated prescribing practice among patients with primary MN (diagnosed 2010-2018) enrolled in the Cure Glomerulonephropathy Network (CureGN) cohort study. We also evaluated the availability of testing for phospholipase A2 receptor (PLA2R) in the contemporary era. RESULTS: Among 361 patients (324 adults and 37 children) with MN who were IST-naïve at biopsy and had at least 6 months of follow-up, 55% of adults and 58% of children initiated IST <6 months after biopsy. Of these, 1 in 5 had no indication for (i.e., urine protein-to-creatinine ratio [uPCR] <4 g/g) or an apparent contraindication to (i.e., an estimated glomerular filtration rate [eGFR] <30 ml/min per 1.73 m2) IST. As first-line IST, half of treated patients received either CYC (16% of adults; 0% of children) or a CNI (40% and 46%, respectively), whereas 1 in 5 received corticosteroid monotherapy (20% and 27%, respectively) and 1 in 6 rituximab (15% and 15%, respectively). More than 80% of surveyed centers had access to PLA2R testing. CONCLUSION: These findings suggest that providers are not aware of, or lack confidence in, current KDIGO guidelines for MN. Treatment patterns observed in this cohort might critically inform the drafting of planned updates to KDIGO guidelines.
引用
- O'Shaughnessy MM, Troost JP, Bomback AS, et al. Treatment Patterns Among Adults and Children With Membranous Nephropathy in the Cure Glomerulonephropathy Network (CureGN). Kidney Int Rep. 2019. PMID: 31844809. doi:10.1016/j.ekir.2019.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。